X4 Pharmaceuticals appoints Francoise de Craecker to Board and Compensation Committee

X4 Pharmaceuticals, Inc

Francoise de Craecker appointed as Class III director effective Oct 14, 2021, term through 2023 annual meeting.
She replaces Alison Lawton on the Compensation Committee; Lawton remains on the Board.
Received initial option to purchase 12,250 shares vesting over three years, with full acceleration on change of control.
Compensation follows standard non-employee director policy as described in the 2021 proxy statement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Francoise de Craecker

Director

XFOR · X4 Pharmaceuticals, Inc

Effective: 2021-10-14
Filed: October 19, 2021, 7:59 PM ET

On October 14, 2021, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Francoise de Craecker as a member of the Company’s Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Francoise de Craecker was appointed as Director at X4 Pharmaceuticals, Inc.

Action: appointed
Role: Director

Exact text from the filing

On October 14, 2021, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Francoise de Craecker as a member of the Company’s Board, effective immediately.

View on SEC.gov

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-21-020237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.